Once a drug target is identified, it often takes decades until a chemical compound is developed that can hit the bullseye and ...

Chemoproteomics screening platform identified novel covalent inhibitors that specifically disrupt RAS-mediated activation of the catalytic subunit of PI 3-kinase alpha (PI3Kα) Newly identified group ...

Matchpoint Therapeutics has publicly launched with $70 million in series A financing and an earlier $30 million in seed money to develop covalent drugs for immune diseases. Its founders include ...

Although covalent drugs have been used for more than a century, the emergence of new tools has helped spur recent advances in the field. Indeed, covalent medicine experienced a resurgence roughly 15 ...

Scientists at the University of Birmingham have developed a new class of MRI contrast agents, improving their stability to ...

Novartis is serving up $60 million to partner with Matchpoint Therapeutics in hopes of getting an oral covalent inhibitor over the line for inflammatory diseases that have been historically difficult ...